UiPath Inc. (NYSE:PATH) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd boosted its holdings in UiPath Inc. (NYSE:PATH) by 7.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,458 shares of the healthcare company’s stock after purchasing an additional 6,357 shares during the quarter. IFM Investors Pty Ltd’s holdings in UiPath were worth $1,983,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in PATH. Vanguard Group Inc. increased its stake in UiPath by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 38,084,858 shares of the healthcare company’s stock worth $946,028,000 after acquiring an additional 334,085 shares during the last quarter. FMR LLC increased its stake in UiPath by 2.9% during the third quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after acquiring an additional 463,032 shares during the last quarter. Norges Bank acquired a new stake in UiPath during the fourth quarter worth about $165,749,000. Senvest Management LLC increased its stake in UiPath by 3.0% during the third quarter. Senvest Management LLC now owns 6,209,655 shares of the healthcare company’s stock worth $106,247,000 after acquiring an additional 181,722 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of UiPath by 2.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301,413 shares of the healthcare company’s stock worth $131,687,000 after buying an additional 119,782 shares during the period. 62.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at UiPath

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total transaction of $359,520.00. Following the sale, the chief financial officer now owns 103,505 shares of the company’s stock, valued at approximately $2,325,757.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 72,000 shares of company stock valued at $1,591,360 in the last quarter. Corporate insiders own 31.03% of the company’s stock.

UiPath Stock Performance

Shares of UiPath stock traded up $0.05 on Friday, reaching $19.46. 4,692,993 shares of the company were exchanged, compared to its average volume of 5,833,793. The company’s 50-day moving average is $22.19 and its two-hundred day moving average is $21.61. The firm has a market cap of $11.07 billion, a price-to-earnings ratio of -114.47 and a beta of 0.96. UiPath Inc. has a 1-year low of $12.38 and a 1-year high of $27.87.

UiPath (NYSE:PATH) last announced its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. The firm had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. As a group, sell-side analysts forecast that UiPath Inc. will post -0.04 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PATH. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of UiPath in a research report on Wednesday, March 20th. DA Davidson increased their price target on UiPath from $20.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, March 14th. Barclays increased their price target on UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, March 15th. KeyCorp assumed coverage on UiPath in a report on Monday, April 8th. They issued an “overweight” rating and a $27.00 price target for the company. Finally, Scotiabank increased their price target on UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.41.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.